Personalized Autologous Transplant for Multiple Myeloma
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the best dose and side effects of mephalan in treating patients
with multiple myeloma who are undergoing stem cell transplant. Chemotherapy drugs, such as
mephalan, work in different ways to stop the growth of cancer cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. This trial uses a
new method of dosing that is based on analysis of each individual's blood levels of melphalan
after receiving a part of the dose, termed pharmacokinetic analysis. This may help to learn
more about how to dose melphalan correctly and which patients are likely to benefit from a
personalized dose.
Phase:
Phase 1
Details
Lead Sponsor:
Emory University
Collaborators:
Gateway for Cancer Research National Cancer Institute (NCI)